Lantern Pharma (LTRN) Price to Book (2020 - 2026)

Lantern Pharma (LTRN) has reported Price to Book for 7 consecutive years, with 16.54 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Book fell 707.66% year-over-year to 16.54; the trailing twelve-month figure through Jun 2026 stood at 16.54 (down 707.66% YoY), and the FY2025 full-year result was 5.22, up 221.42% from the prior year.
• Price to Book eased to 16.54 in Q2 2026 per LTRN's latest filing, from 4.47 in the prior quarter.
• Across five years, Price to Book topped out at 5.22 in Q4 2025 and bottomed at 16.54 in Q2 2026.
• Historically, Price to Book has averaged 1.06 across 5 years, with a median of 1.38 in 2023.
• The sharpest annual moves came in 2025 and 2026: Price to Book surged 236.64% in 2025, then tumbled 707.66% in 2026.
• Over 5 years, Price to Book stood at 1.17 in 2022, then dropped by 4.15% to 1.12 in 2023, then soared by 44.76% to 1.62 in 2024, then soared by 221.42% to 5.22 in 2025, then slumped by 416.88% to 16.54 in 2026.
• According to Business Quant data, Price to Book over the past three periods registered 16.54, 4.47, and 5.22 for Q2 2026, Q1 2026, and Q4 2025 respectively.